Darryn Bampton has over 25 years’ experience in the pharmaceutical industry, principally in regulatory and clinical development roles.

He is Chief Development Officer at Zucero Therapeutics and has previously held senior management positions at Progen Pharmaceuticals Limited and Constella Group.

Mr Bampton has held regulatory affairs roles in cross-functional drug development teams for several marketed products, including the orphan oncology drug Savene (TopoTarget), and the anti-infective drugs Cubicin (Chiron), and Tygacil (Wyeth). Since 2016, he has overseen the clinical program of the immunomodulator Pixatimod, which is currently in Phase 2 in several oncology indications.

Mr Bampton holds a Master of Medical Science degree from the University of New South Wales and a Post-graduate diploma in Regulatory Affairs from the University of Wales (UK).